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Abstract
The capacity of estrogen and stilbene derivatives to modulate the activity of superoxide dismutases in relation with their estrogenic 
properties has been studied. The properties of trans-resveratrol (3,5,4′-trihydroxystilbene) and its analogues, 4-hydroxystilbene, 4,4′-
dihydroxystilbene, 3,5-dihydroxystilbene, 3,5,4′-trimethoxystilbene and 4,4′-dihydroxy-3,5,3′,5′-tetramethylstilbene were compared to 17-
estradiol and its ana-logues (2-methoxyestradiol, estrone, 2-hydroxyestradiol and 2-methoxyestrone). Measurement of estrogen receptor- 
(ER-) binding capacity was carried out by a receptor competitor assay associated with fluorescence polarisation detection. The superoxide 
dismutase (SOD) modulation activity was followed with a spectrophotometric assay using the sequence xanthine/xanthine oxidase-2,3-
bis[2-methoxy-4-nitro-sulfo-phenyl]-2H-tetrazolium-5-carboxanilide (X/XO-XTT). The structure–activity relationship was different for the 
two series tested. In the estrogenic series, a compound which does not inhibit SOD, is recognized by the ER-. In contrast for the stilbenic 
series both properties are parallel each other.
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1. Introduction
Resveratrol (3,5,4′-trihydroxy-trans-stilbene), a natural
phytoalexin found in grapes and wine, shows antioxi-
dant, estrogenic and antiproliferative activities. The anti-
carcinogenic properties of resveratrol and of some of its
derivatives have been demonstrated on different models
but the mechanisms by which it acts still remain incom-
pletely understood. Studies on the structural determinants
which may be important have been reported: number
and position of hydroxyl groups, intramolecular hydrogen
bonding, stereoisomery, redox potential [1–5]. Consider-
ing the relation between antiestrogenic activity and an-
tiproliferative properties, recent studies have shown that
2-hydroxyestradiol and 2-methoxyestradiol which are es-
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trogen derivatives that cannot bind the estrogen receptor,
kill human leukaemia cells but not normal lymphocytes
[6], and are cell growth inhibitors [7]. One mechanism
proposed explains these antiproliferative activities by an
inhibition of superoxide dismutase (SOD) by these antie-
strogens [6,8,9]. Inhibition of SOD causes accumulation of
cellular superoxide radical and, after free radical-mediated
damage, leads to apoptosis of the cancer cells. Taking these
recent results into account, we were interested in study-
ing the ability of stilbene derivatives (Fig. 1) to modulate
the activity of superoxide dismutases in relation with their
estrogenic properties. The properties of trans-resveratrol
were compared to stilbene derivatives which were synthe-
sised as previously reported [1]. Five estrogen derivatives
(Fig. 2) were also introduced in this study, among them
17-estradiol as a control for estrogen receptor- (ER-)
binding assays and 2-methoxyestradiol because it cannot
bind ER- and it has been proposed as an inhibitor of SOD
[6]. Measurement of estrogen receptor- (ER-) binding
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Fig. 1. Stilbenic compounds studied, S1–S6.
capacity was carried out by a receptor competitor assay as-
sociated with fluorescence polarisation detection [10]. The
SOD modulation activity has been evaluated with a spec-
trophotometric assay using the sequence xanthine/xanthine
oxidase-2,3-bis[2-methoxy-4-nitro-sulfo-phenyl]-2H-
tetrazolium-5-carboxanilide (X/XO-XTT) [11].
2. Experimental
2.1. Reagents
Reagents purchased from Sigma–Aldrich (St Quentin
Fallavier, France) were sodium carbonate (Na2CO3),
EDTA (disodium salt dihydrate), XTT sodium salt (2,3-
bis[2-methoxy-4-nitro-sulfo-phenyl]-2H-tetrazolium-5-car-
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Fig. 2. Estrogenic compounds studied, E1–E5.
boxanilide), xanthine(2,6-dihydroxypurine), xanthine oxi-
dase (EC 1.1.3.22; 0.6 units/mg protein) from buttermilk,
Mn-SOD (EC 1.15.1.1; 4400 units/mg protein) and Fe-SOD
(EC 1.15.1.1; 2530 units/mg protein) from bovine erythro-
cytes, 17-estradiol (E1), estrone (E2), 2-hydroxyestradiol
(E3), 2-methoxyestrone (E4), 2-methoxyestradiol (E5) and
resveratrol (3,5,4′-trihydroxystilbene/S4). Stilbene deriva-
tives: 4-hydroxystilbene (S1), 4,4′-dihydroxystilbene (S2),
3,5-dihydroxystilbene (S3), 3,5,4′-trimethoxystilbene (S5)
were synthesized as previously reported [1]. 4,4′-Dihydroxy-
3,5,3′,5′-tetramethylstilbene (S6) was synthesized as re-
ported in [12]. All solutions were prepared with water
purified by a Milli-Q system (Millipore, Paris). XTT and
xanthine were dissolved in a 50 mM sodium carbonate
buffer (pH 9.8) at room temperature and at 45 ◦C, respec-
tively.
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Fig. 3. In vitro SOD assay.
2.2. In vitro SOD assay
The SOD assay using the X/XO-XTT system was car-
ried out as previously reported [11]. The samples tested
(final volume 2 ml), distributed on a 24-well microplate
(Greiner bio-one, Poitiers, France) were prepared by addi-
tion to a 50 mM sodium carbonate buffer (pH 9.8): (i) 67l
each of 3 mM EDTA, 0.8 mM XTT, 3 mM xanthine; (ii)
Fig. 4. Direct O2•− scavenging and/or inhibition of XO by the compounds tested (100M).
the compound tested at a final concentration in the assay
of 1, 10 and 100M; (iii) SOD with a concentration that
allowed complete superoxide radical consumption. Instead
of SOD, buffer was added to evaluate the XO inhibition
by the compound tested (SOD-free control). The reaction
was initiated by the addition of XO solution at a concentra-
tion of 60 mU ml−1 in the assay. The absorbance change at
470 nm for 30 min was monitored with a microplate reader
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(BMG Polarstar from BMG Labtechnologies, Champigny
sur Marne, France) thermostated at 25 ◦C. The relative SOD
modulation activities (RA) of the compound tested were
expressed as:
RA =
[
1− (c− b)
a− b
]
× 100%
where a is the absorbance without SOD in the presence
of the compound tested, b the absorbance with SOD and
without the compound tested, c is the absorbance with SOD
in the presence of the compound tested.
2.3. In vitro β-receptor assay
The affinity of the compounds tested for the human
estrogen receptor- (ER-) was assayed using the estro-
gen receptor- competitor assay distributed by Panvera
Co. (Takara Biomedical Europe, Gennevilliers, France)
[10]. In this assay ER- is added to a fluorescent estrogen
(Fluormone®, ES2) ligand to form an ES2/ER- complex
with high fluorescence polarisation. The complex is then
added to the estrogen competitor, and the compound tested
in microtiter wells. The shift in polarisation after incubation
in the dark at 25 ◦C for 2 h in the presence of the com-
pound tested is used to determine its relative affinity for
ER-. In each well (Falcon, black round microtiter plates,
96 wells) (Becton Dickinson Labware Europe, Le Pont de
Claix, France), the concentrations of ER-, fluormone ES2
and the compound tested were fixed at 20 nM, 2 nM and
20M, respectively. Fluorescence polarisation was mon-
itored with the microplate reader (BMG Polarstar) with
485 nm excitation and 530 nm emission interference filters.
3. Results and discussion
3.1. In vitro SOD assay
The superoxide dismutase assay based on the use
of the tetrazolium salt XTT was used to evaluate the
capacity of estrogen and stilbene derivatives to inhibit or
modulate the SOD activity. Fig. 3 presents the principle of
the SOD assay which consists in generating the superoxide
radical, O2•−, with the xanthine/xanthine oxidase system.
The O2•− radical causes XTT reduction, leading to the
formation of reddish water-soluble formazan with an ab-
sorbance maximum at 470 nm. In the presence of SOD, the
O2•− radical dismutation reaction (k ≈ 5×105 M−1 s−1) to
hydrogen peroxide (H2O2) is considerably accelerated (k ≈
1.6×109 M−1 s−1 at physiological pH). As a consequence of
O2•−, consumption by the SOD, the absorbance at 470 nm
is reduced in a concentration-dependent way. In a first step,
assays without SOD (controls) were carried out to evaluate
the capacity of the compounds tested to scavenge the super-
oxide radical directly and/or to inhibit the xanthine oxidase
(Fig. 4). Compounds S6 and E3 led to a strong decrease in
absorbance (68 and 55%, respectively) at 100M and may
react directly with O2•− or inhibit XO. Other compounds
tested produced a weaker absorbance decrease between 0
and 28%. These preliminary controls are essential to avoid
misinterpretation of the potential activity of the compound
tested. It can be noted that E5 (2-methoxyestradiol) does not
scavenge the superoxide radical directly and does not inhibit
the XO enzyme thus confirming results previously reported
by Kachadourian [13]. The antioxidant properties of some
stilbenic compounds (S1, S2, S3 and S4) towards O2•− rad-
icals in a DMSO medium have been previously reported by
Privat et al. [1]. This study gave the IC50 values which cor-
respond to the stilbene concentration necessary for a 50%
decrease of the DMPO-OOH EPR signal intensity according
to a control performed without additives. IC50 values varied
from 820M for 4,4-dihydroxystilbene (S2) to 1680M
3,5-dihydroxystilbene (S3). These concentrations were
8–16 times higher than those used in the X/XO-XTT assay
in this work with a maximum concentration of 100M. By
using a lower concentration of the compound tested, the
scavenging effect is minimised. Moreover, possible inter-
ferences which could be observed by direct reduction of
XTT (via the direct reaction of the compound tested with
the probe) without involvement of superoxide anion, could
be suppressed by simple dilution of the sample [14].
In a second step, the critical SOD concentration lead-
ing to total superoxide radical consumption was looked for.
For fixed concentrations of XO (60 mU ml−1) and XTT
(0.8 mM) in the assay,Fig. 5A and B show absorbance ver-
sus time for concentrations of Mn-SOD and Fe-SOD be-
tween 0 and 10g ml−1. In the absence of SOD in the as-
say, the absorbance increases linearly during the first 12 min.
A small concentration of Mn-SOD (0.1g ml−1) in the as-
say is sufficient to induce rapid consumption of superoxide.
Consequently, compared to the assay without SOD and for
a fixed reaction time, a significant decrease of absorbance
is observed when the SOD concentration is increased. In-
creasing the SOD concentration leads to the conditions for
absorbance equal to zero which means complete superox-
ide consumption by the SOD (Fig. 6). Thus, the condi-
tions for a complete superoxide consumption (absorbance
at 30 min ≤ 0.004) were obtained: [Mn-SOD] = 2g ml−1
and [Fe-SOD] = 8g ml−1. Using these concentrations,
the capacity of the natural (E1–E5) and synthetic (S1–S6)
estrophenols to modulate the SOD activity was evaluated.
Fig. 7 presents the absorbance variation in the X/XO-XTT
assay versus the concentration of 2-methoxyestradiol (E5)
(0–100M). Absorbance was corrected taking into account
the direct scavenging activity and/or XO inhibition activity
in the control X/XO-XTT assays of the compound tested
(Fig. 4). Since E5 does not directly scavenge the O2•−
radical or inhibit the XO enzyme (Fig. 4), the results pre-
sented in Fig. 7 confirm the ability of E5 to inhibit SOD.
SOD inhibition has recently been reported in different pa-
pers pointing out the strong interest of these molecules in
anticancer research [4–6,8,9,15]. IC50 values represent the
concentration that inhibits 50% of the SOD activity and val-
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Fig. 7. Inhibition of Mn- and Fe-SOD by different concentrations of 2-methoxyestradiol (E5).
are less contrasted. Whereas E1 and E2 present a very weak
modulating activity, E3, E4 and E5 decreased the SOD
activities (to 55–25%) at 100M.
It should be emphasised that a larger amount of Fe-SOD
than Mn-SOD was necessary to dismutate the total amount
Fig. 8. Relative activities of SODs vs. the compound concentration.
of O2•− generated by the X/XO system in our experimen-
tal conditions. This lower activity of Fe-SOD compared to
Mn-SOD leads to the appearance of a higher activity of
the compounds against Fe-SOD at the same concentration
tested.
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Fig. 9. In vitro estrogenic receptor- assay (ER-).
3.2. In vitro β receptor assay
Fig. 9 illustrates the competitive assay used to assess the
affinity of the series tested (E1–E5, S1–S6) for the human
estrogen receptor- (ER-). The concentration that results
in a half- maximum shift in the polarisation gives the IC50
of the compound tested. The IC50 value corresponds to the
concentration of competitor needed to displace half of the
bound ligand. Fig. 10 presents the competition binding as-
say curve for the 17-estradiol (E1) leading to an IC50 of
about 20 nM. This result is in agreement with published data
[10]. To compare the binding capacity of the compounds
to ER-, a fixed concentration was used (1.0 × 10−5 M).
The compounds S3, S5, S6, E3, E4 and E5 appear as
non- or very weak competitors of fluormone® ES2 while
S1, S2, S4, E1 and E2 are clearly recognized by ER-
(Fig. 11).
Overall examination of the results shows that the two se-
ries studied remain distinct. In the estrogen series, when a
compound does not inhibit SOD, it is recognized by ER-.
In this way, E3 and E4 behave like 2-methoxyestradiol
(E5). In the stilbene series, when a compound presents a
SOD-inhibiting-like activity, it is also recognized by ER-
and when it has no SOD inhibiting activity, it is not rec-
ognized. The exception is S6 for which a strong O2•−
scavenging activity and/or an inhibition of the XO enzyme
was observed in the control experiment. Inhibition of SOD
activity and ER- recognition by stilbene compounds seems
linked to the presence of the OH group on the R2 or R5 posi-
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Fig. 10. ER- binding assay with 17-estradiol (E1).
tions (S1, S2, S4). In the estrogen series, the R2 substituent
is not preponderant for the SOD inhibiting activity or for
ER- recognition. The R1 substituent, on the contrary, plays
an important role: the substitution of the H atom by OH or
OCH3 reverses the activities. These structural considerations
are in agreement with previously reported results [5–9,16].
Our results are consistent with the previous study of Huang
et al. [6]. First of all, the order and magnitude of SOD in-
hibition by the estrogen derivatives is respected. Secondly,
we confirm that 2-methoxyestradiol (E5) has no effect on
xanthine oxidase (inhibition and/or O2•− scavenging) and
that this compound inhibits SOD activity or, in all cases,
modulates the enzyme activity. Chemical modifications at
the 2-carbon substituent (R1: OH, OCH3) of the estrogen
derivatives are essential for SOD inhibition, which is the
case for E5, E3 and E4. In contrast, 17-estradiol (E1) and
estrone (E2), which lack the carbon-2 modification, showed
minimal activity against SOD. Interestingly, a similar ef-
fect is found in the stilbene series: 4-hydroxystilbene (S1),
4,4′-dihydroxystilbene (S2) and 3,5,4′-trihydroxystilbene
(S4) which have an OH group at the 4 and/or 4′-carbon
(R2 or R5 substituent) present the most effective inhibi-
tion of SOD. 3,5-Dihydroxystilbene (S3), which lacks the
4 and/or 4′-carbon OH group, does not present a modu-
lating effect on the SOD activity. An exception is found
with 4,4′-dihydroxy-3,5,3′,5′-tetramethylstilbene (S6),
though it has the 4 and/or 4′-carbon OH group, it is not a
SOD inhibitor. This might be due to the steric effects of the
methyl groups.
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Fig. 11. ER- binding assay with fixed concentration of competitor (1× 10−5 M).
The preponderant effect of the hydroxyl group in the 4′
position in stilbene derivatives was underlined by Stivala
et al. [5] who showed that the presence of 4′-OH together
with a trans-configuration (4′-hydroxylstyryl moiety) was
absolutely required for the inhibition of fibrosarcoma cell
proliferation. In this case, the active O2•− production and
low SOD activity (due to inhibition by the compound with
hydroxyl group in 4′ position) may render the malignant cells
highly dependent on SOD for survival and hence sensitive
to SOD inhibition [5].
Inhibition of superoxide dismutases by the 2-methoxyes-
tradiol initially described [6] has been confirmed twice
[8,16]. Another study [17] has found a selective inhibition
of Fe- versus Cu/Zn-SOD by 2,3-dihydroxybenzoic acid
derivatives. Although this finding was questioned in one
study [13], our observations confirm that 2-methoxyestradiol
inhibits SOD activity and that some stilbene derivatives can
effectively modulate superoxide dismutase activity. More-
over, in the stilbene series, the structure–activity relations
established for the modulation of SOD activity appear to
be applicable to ER- recognition. Stilbene compounds
which have a hydroxyl group at the 4 and/or 4′-carbon are
recognized by ER-. 3,5-Dihydroxystilbene (S3), which
lacks this 4 and/or 4′ substituent, is clearly not recog-
nized by ER-. As for the modulation of the SOD activity,
an exception is found with the 4,4′-dihydroxy-3,5,3′,5′-
tetramethylstilbene (S6), likely because of steric effects by
the methyl groups. In the estrogen series, our results con-
firm that 2-methoxyestradiol (E5) and 2-hydroxyestradiol
(E3) have little affinity for ER- [7,9]. Recognition by the
estrogen receptor seems linked to the presence of a hydro-
gen atom on the 2-carbon (R1 substituent) coupled with
the hydroxyl group on the 3-carbon. This observation is
respected in the stilbene series: the recognition is effective
when a hydroxyl group is located at the 4 and/or 4′-carbon
and when a hydrogen atom is present on the vicinal
carbon.
In conclusion, when compounds in the estrogen series
are inhibitors of SOD (or not), they are not (or are) recog-
nized by ER-; in the stilbene series both properties exist
together.
Acknowledgements
This work was supported by the Conseil Régional
Midi-Pyrénées and its Health-Food Network, France. Vin-
cent Farines thanks the Association “Société de Secours des
Amis des Sciences” for his fellowship.
References
[1] C. Privat, J.P. Telo, V. Bernardes-Genisson, A. Vieira, J.P. Souchard,
F. Nepveu, J. Agric. Food Chem. 50 (2002) 1213.
[2] J.G. Fang, M. Lu, Z.H. Chen, H.H. Zhu, Y. Li, L. Yang, L.M. Wu,
Z.L. Liu, Chem. Eur. J. 8 (18) (2002) 4191.
[3] J.S. Wright, E R. Johnson, G.A. Dilabio, J. Am. Chem. Soc 123
(2001) 1173.
[4] J.P. Basly, F. Marre-Fournier, J.C. Le Bail, G. Habrioux, A.J. Chulia,
Life Sci. 66 (9) (2000) 769.
[5] L.A. Stivala, M. Savio, F. Carafoli, P. Perucca, L. Bianchi, G. Maga,
L. Forti, U.M. Pagnoni, A. Albini, E. Prosperi, V. Vannini, J. Biol.
Chem. 276 (25) (2001) 22586.
[6] P. Huang, L. Feng, E.A. Oldahm, M.J. Keating, W. Plunkett, Nature
407 (2000) 390.
[7] R.K. Dubey, D.G. Gillespie, P.J. Keller, B. Imthurn, L.C. Zacharia,
E.K. Jackson, Hypertension 39 (2) (2002) 418.
[8] J. Golab, D. Nowis, M. Skrzycki, H. Czeczot, A. Barañczyk-KuŸma,
G.M. Wilczyñski, M. Makowski, P. Mróz, K. Kozar, R. Kamiñski,
A. Jalili, M. Kopeæ, T. Grzela, M. Jakóbisiak, J. Biol. Chem. 278 (1)
(2003) 407.
[9] T.M. LaVallee, X.H. Zhan, C.J. Herbstritt, E.C. Kough, S.J. Green,
V.S. Pribluda, Cancer Res. 62 (2002) 3691.
[10] R. Bolger, T.E. Wiese, K. Ervin, S. Nestich, W. Checovich, Environ.
Health Perspect. 106 (9) (1998) 551.
[11] H. Ukeda, S. Maeda, T. Ishii, M. Sawamura, Anal. Biochem. 251
(1997) 206.
60.0 
"' <J 50.0 
= 
"' <J
"' i::: ,-., 40.0 0 ~ 
= ~ 
= = 
-; 0 ;:: 30.0 ] ~ 
"' 
.... ·c: 
0 .!S 
= 8. 20.0 0 ;:: 
:s 
:a 10.0 
= .... 
0.0 
Sl S2 S3 S4 S5 S6 El E2 E3 E4 E5 
Compound tested 
[12] R.H. Sieber, Liebigs Ann. Chem. 730 (1969) 31.
[13] R. Kachadourian, S.I. Liochev, D.E. Cabelli, M.N. Patel, I. Fridovich,
B.J. Day, Arch. Biochem. Biophys. 392 (2) (2001) 349.
[14] T. Shimamura, S. Maeda, H. Ukeda, M. Sawamura, J. Jpn. Soc.
Biosci. Biotechnol. Biochem. 72 (10) (1998) 1181.
[15] N. Kuwajerwala, E. Cifuentes, S. Gautam, M. Menon, E.R. Barrack,
G. Prem Veer Reddy, Cancer Res. 62 (2002) 2488.
[16] L. Wood, M.P. Leese, B. Leblond, L.W.L. Woo, D. Ganeshapillai,
A. Purohit, M.J. Reed, B.V.L. Potter, G. Packham, Anticancer Drug
Des. 16 (2002) 209.
[17] L. Soulère, C. Viodé, J. Perié, P. Hoffman, Chem. Pharm. Bull.
50 (5) (2002) 578.
